Importance Breast cancer will be diagnosed in 12% of women in the United States over the
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …

… Of these, the PALLAS and PENELOPE-B studies using palbociclib did not show
improvement in disease-free survival, while the MONARCH-E trial using abemaciclib did find …

Purpose To update the 2003 American Society of Clinical Oncology technology assessment
on adjuvant use of aromatase inhibitors. Recommendations Based on results from multiple …

Brain metastases are associated with a dismal prognosis. Whether brain metastases harbor
distinct genetic alterations beyond those observed in primary tumors is unknown. We …

… Winer met at the conclusion of the conference to review the new information presented and
consider treatment recommendations for broad application over the next 2 years. As in the …

The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial
new evidence on locoregional and systemic therapies for early breast cancer. Further …

Purpose: Using a 2 2 factorial design, we studied the adjuvant chemotherapy of women with
axillary node–positive breast cancer to compare sequential doxorubicin (A), paclitaxel (T), …

Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative
and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is …

… Once the PALOMA 2 data is published the MCBS will be updated with an e-update made
available through the ESMO guidelines website. For the use of palbociclib as 2nd line therapy, …

… This review utilized electronic techniques (Medline, the Cochrane Library, Best Evidence [ACP
Journal Club and Evidence-Based Medicine], DARE [Database of Abstract of Reviews of …